Amgen (AMGN) says late-stage testing of its Aranesp drug candidate failed to meet its primary endpoint of reducing deaths in heart-failure patients. The six-year trial worked with nearly 2,300 patients with symptomatic systolic heart failure and anemia by attempting to treat their anemia caused by kidney dialysis.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Mon, 3:02PM)
at Zacks.com (Sat, 7:36PM)
at Benzinga.com (Thu, 1:25PM)
at Zacks.com (Thu, 11:20AM)
at Benzinga.com (Feb 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs